394 CONCORDANCE IN MOLECULAR MARKER STATUS BETWEEN BLADDER TUMORS AT TIME OF TRANSURETHRAL RESECTION AND SUBSEQUENT RADICAL CYSTECTOMY: RESULTS OF A 5-YEAR PROSPECTIVE STUDY

[1]  Y. Lotan,et al.  Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy , 2014, BJU international.

[2]  Y. Lotan,et al.  Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. , 2013, European urology.

[3]  S. Shariat,et al.  Accurate preoperative prediction of non‐organ‐confined bladder urothelial carcinoma at cystectomy , 2013, BJU international.

[4]  A. Scott,et al.  Current Role of PET, CT, MR for Invasive Bladder Cancer , 2013, Current Urology Reports.

[5]  H. Grossman,et al.  Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. , 2012, Urologic oncology.

[6]  I. Ellis,et al.  Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast , 2012, Histopathology.

[7]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[8]  David A. Green,et al.  Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes , 2012, Current Urology Reports.

[9]  Y. Lotan,et al.  Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. , 2012, The Journal of urology.

[10]  Y. Lotan,et al.  Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer , 2011, Cancer.

[11]  T. D’alfonso,et al.  Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed , 2010, The American journal of surgical pathology.

[12]  Yair Lotan,et al.  Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. , 2010, European urology.

[13]  U. Capitanio,et al.  Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.

[14]  Yair Lotan,et al.  Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy , 2008, Cancer.

[15]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[16]  Y. Lotan,et al.  Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness , 2007, Modern Pathology.

[17]  Yair Lotan,et al.  Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.

[18]  Y. Lotan,et al.  Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.

[19]  Y. Lotan,et al.  Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. , 2006, Human pathology.

[20]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[21]  Yair Lotan,et al.  Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.

[22]  Yair Lotan,et al.  Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.

[23]  Michael W Kattan,et al.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Roehrborn,et al.  Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation , 2006, BJU international.

[25]  S. Shariat,et al.  p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[27]  W. Benedict,et al.  Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. , 2001, International journal of radiation oncology, biology, physics.

[28]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .